keyword
https://read.qxmd.com/read/38632607/superior-protection-in-a-relapsing-plasmodium-cynomolgi-rhesus-macaque-model-by-a-chemoprophylaxis-with-sporozoite-immunization-regimen-with-atovaquone-proguanil-followed-by-primaquine
#21
JOURNAL ARTICLE
Kosol Yongvanitchit, Utaiwan Kum-Arb, Amporn Limsalakpetch, Rawiwan Im-Erbsin, Ratawan Ubalee, Michele D Spring, Brian A Vesely, Norman Waters, Sathit Pichyangkul
BACKGROUND: To gain a deeper understanding of protective immunity against relapsing malaria, this study examined sporozoite-specific T cell responses induced by a chemoprophylaxis with sporozoite (CPS) immunization in a relapsing Plasmodium cynomolgi rhesus macaque model. METHODS: The animals received three CPS immunizations with P. cynomolgi sporozoites, administered by mosquito bite, while under two anti-malarial drug regimens. Group 1 (n = 6) received artesunate/chloroquine (AS/CQ) followed by a radical cure with CQ plus primaquine (PQ)...
April 17, 2024: Malaria Journal
https://read.qxmd.com/read/38632563/db-1310-an-adc-comprised-of-a-novel-anti-her3-antibody-conjugated-to-a-dna-topoisomerase-i-inhibitor-is-highly-effective-for-the-treatment-of-her3-positive-solid-tumors
#22
JOURNAL ARTICLE
Xi Li, Jun Yao, Chen Qu, Lan Luo, Bing Li, Yu Zhang, Zhongyuan Zhu, Yang Qiu, Haiqing Hua
BACKGROUND: HER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Multiple HER3-targeting antibodies and antibody-drug conjugates (ADCs) were developed for the solid tumor treatment, however none of HER3-targeting agent has been approved for tumor therapy yet. We developed DB-1310, a HER3 ADC composed of a novel humanized anti-HER3 monoclonal antibody covalently linked to a proprietary DNA topoisomerase I inhibitor payload (P1021), and evaluate the efficacy and safety of DB-1310 in preclinical models...
April 17, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38632501/phase-i-ii-clinical-trial-of-efficacy-and-safety-of-egcg-oxygen-nebulization-inhalation-in-the-treatment-of-covid-19-pneumonia-patients-with-cancer
#23
JOURNAL ARTICLE
Xiaoyan Yin, Wanqi Zhu, Xiaoyong Tang, Guangjian Yang, Xianguang Zhao, Kaikai Zhao, Liyang Jiang, Xiaolin Li, Hong Zhao, Xin Wang, Yuanyuan Yan, Ligang Xing, Jinming Yu, Xiangjiao Meng, Hanxi Zhao
BACKGROUND: The antiviral drug Nirmatrelvir was found to be a key drug in controlling the progression of pneumonia during the infectious phase of COVID-19. However, there are very few options for effective treatment for cancer patients who have viral pneumonia. Glucocorticoids is one of the effective means to control pneumonia, but there are many adverse events. EGCG is a natural low toxic compound with anti-inflammatory function. Thus, this study was designed to investigate the safety and efficacy of epigallocatechin-3-gallate (EGCG) aerosol to control COVID-19 pneumonia in cancer populations...
April 17, 2024: BMC Cancer
https://read.qxmd.com/read/38632457/a-randomized-double-blind-placebo-controlled-phase-iia-clinical-study-on-investigating-the-efficacy-and-safety-of-sph3127-tablet-in-patients-with-essential-hypertension
#24
JOURNAL ARTICLE
Fang Wang, Ling Liu, Hongyun Ruan, Xiaoping Chen, Yue Zhang, Zaixin Yu, Yuhui Li, Yang Guan, Jiguang Wang, Kai Huang, Shunjiang Yu, Yuanyuan Cao, Cungang Ding, Lin Chang, Yaohua Huang, Xiangjuan Chen, Qiang Lv, Changsheng Ma
Around 70% of patients diagnosed with hypertension exhibit increased levels of renin. SPH3127, an inventive renin inhibitor, has shown favorable tolerability and sustained pharmacodynamic inhibitory impact on plasma renin activity (PRA) during previous phase I trials. This phase II study was conducted to investigate the efficacy and safety of SPH3127 in patients with essential hypertension. This study was conducted in patients with mild to moderate essential hypertension, utilizing a randomized, double-blind, placebo-controlled design...
April 17, 2024: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://read.qxmd.com/read/38632138/comparison-of-old-and-new-systemic-treatments-for-moderate-to-severe-atopic-dermatitis
#25
REVIEW
Hyun J Yim, Tiffany Jean, Peck Y Ong
PURPOSE OF REVIEW: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD. RECENT FINDINGS: Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious...
April 18, 2024: Current Allergy and Asthma Reports
https://read.qxmd.com/read/38632021/the-effect-of-statins-on-the-risk-of-anti-tuberculosis-drug-induced-liver-injury-among-patients-with-active-tuberculosis-a-cohort-study
#26
JOURNAL ARTICLE
Chun-Kai Huang, Jei-Yie Huang, Chin-Hao Chang, Shang-Jie Tsai, Chin-Chung Shu, Hao-Chien Wang, Kuo-Liong Chien
BACKGROUND: Tuberculosis (TB) remains prevalent worldwide, and anti-TB drugs are associated with drug-induced liver injury (DILI). Statins have pleiotropic effects which may decrease inflammation and achieve immunomodulation. However, few studies have investigated the pleiotropic effects of statins on the risk of DILI. The purpose of this study was to investigate whether statins prevent anti-tuberculosis DILI among active TB patients on standard anti-TB drug therapy. METHODS: We conducted a hospital-based retrospective cohort study using claims data from the Integrated Medical Database of National Taiwan University Hospital (NTUH-iMD)...
April 8, 2024: Journal of Microbiology Immunology and Infection
https://read.qxmd.com/read/38631990/a-phosphodiesterase-4-pde4-inhibitor-amlexanox-reduces-neuroinflammation-and-neuronal-death-after-pilocarpine-induced-seizure
#27
JOURNAL ARTICLE
Hyun Wook Yang, A Ra Kho, Song Hee Lee, Beom Seok Kang, Min Kyu Park, Chang Jun Lee, Se Wan Park, Seo Young Woo, Dong Yeon Kim, Hyun Ho Jung, Bo Young Choi, Won Il Yang, Hong Ki Song, Hui Chul Choi, Jin Kyu Park, Sang Won Suh
Epilepsy, a complex neurological disorder, is characterized by recurrent seizures caused by aberrant electrical activity in the brain. Central to this study is the role of lysosomal dysfunction in epilepsy, which can lead to the accumulation of toxic substrates and impaired autophagy in neurons. Our focus is on phosphodiesterase-4 (PDE4), an enzyme that plays a crucial role in regulating intracellular cyclic adenosine monophosphate (cAMP) levels by converting it into adenosine monophosphate (AMP). In pathological states, including epilepsy, increased PDE4 activity contributes to a decrease in cAMP levels, which may exacerbate neuroinflammatory responses...
April 16, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38631865/the-influence-of-emodin-succinyl-ethyl-ester-on-non-alcoholic-steatohepatitis-induced-by-a-diet-high-in-fructose-cholesterol-and-fat-in-mice
#28
JOURNAL ARTICLE
Yanxue Wang, Liang Li, Lingling Chen, Jinlei Xia, Tongli Wang, Lei Han, Liang Cao, Zhenzhong Wang, Wei Xiao, Shan Jiang
Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatic steatosis and evidence of hepatocyte injury (ballooning) and inflammation, with or without liver fibrosis. In this study, after 12 weeks of induction, the mice were treated with emodin succinyl ethyl ester (ESEE) for four weeks at doses of 10/30/90 mg/kg/day. The blood analysis of experimental endpoints showed that ESEE exhibited significant therapeutic effects on the progression of disorders of glycolipid metabolism and the induced liver injury in the model animals...
April 18, 2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38631564/%C3%AE-caryophyllene-inhibits-heroin-self-administration-but-does-not-alter-opioid-induced-antinociception-in-rodents
#29
JOURNAL ARTICLE
Ewa Galaj, Guo-Hua Bi, Zheng-Xiong Xi
A growing body of research indicates that β-caryophyllene (BCP), a constituent present in a large number of plants, possesses significant therapeutic properties against CNS disorders, including alcohol and psychostimulant use disorders. However, it is unknown whether BCP has similar therapeutic potential for opioid use disorders. In this study, we found that systemic administration of BCP dose-dependently reduced heroin self-administration in rats under an FR2 schedule of reinforcement and partially blocked heroin-enhanced brain stimulation reward in DAT-cre mice, maintained by optical stimulation of midbrain dopamine neurons at high frequencies...
April 15, 2024: Neuropharmacology
https://read.qxmd.com/read/38631503/the-antidiabetic-drug-ipragliflozin-induces-vasorelaxation-of-rabbit-femoral-artery-by-activating-a-kv-channel-the-serca-pump-and-the-pka-signaling-pathway
#30
JOURNAL ARTICLE
Minju Park, Seo-Yeong Mun, Wenwen Zhuang, Junsu Jeong, Hye Ryung Kim, Hongzoo Park, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun, Hongliang Li, Won Sun Park
We explored the vasorelaxant effects of ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, on rabbit femoral arterial rings. Ipragliflozin relaxed phenylephrine-induced pre-contracted rings in a dose-dependent manner. Pre-treatment with the ATP-sensitive K+ channel inhibitor glibenclamide (10 μM), the inwardly rectifying K+ channel inhibitor Ba2+ (50 μM), or the Ca2+ -sensitive K+ channel inhibitor paxilline (10 μM) did not influence the vasorelaxant effect. However, the voltage-dependent K+ (Kv) channel inhibitor 4-aminopyridine (3 mM) reduced the vasorelaxant effect...
April 15, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38630908/safety-and-efficacy-of-belantamab-mafodotin-with-pembrolizumab-in-patients-with-relapsed-or-refractory-multiple-myeloma
#31
JOURNAL ARTICLE
Attaya Suvannasankha, Nizar Bahlis, Suzanne Trudel, Katja Weisel, Christian Koenecke, Albert Oriol, Peter M Voorhees, Aranzazu A Alonso, Natalie S Callander, María-Victoria Mateos, Nishitha Reddy, Shawn Hakim, John LaMacchia, Nashita Patel, Danaé Williams, Roxanne C Jewell, Xiangdong Zhou, Ira Gupta, Joanna Opalinska, Ajay K Nooka
BACKGROUND: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell-mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM. METHODS: DREAMM-4 (NCT03848845) was an open-label, single-arm, phase 1/2 study divided into dose-escalation (part 1) and dose-expansion (part 2) phases...
April 17, 2024: Cancer
https://read.qxmd.com/read/38630860/design-of-dry-powder-inhalers-to-improve-patient-outcomes-it-s-not-just-about-the-device
#32
REVIEW
Jeffry G Weers
INTRODUCTION: Up to 50% of asthma/COPD patients make critical errors in dose preparation and dose inhalation with current marketed DPIs which negatively impact clinical outcomes. Others fail to adhere to their chronic treatment regimen. AREAS COVERED: For this review, we describe how a human-factors approach to design of a dry powder inhaler can be used to improve usability, proficiency, and functionality of DPIs, while effectively mitigating critical errors associated with DPIs...
April 17, 2024: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/38630781/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-from-a-phase-i-study-of-simlukafusp-alfa-fap-il2v-in-advanced-metastatic-solid-tumors
#33
JOURNAL ARTICLE
Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg, Morten Mau-Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, Maria E Rodriguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
PURPOSE: Simlukafusp alfa (FAP-IL2v), a tumor-targeted immunocytokine, comprising an interleukin-2 variant moiety with abolished CD25 binding fused to human immunoglobulin G1, is directed against fibroblast activation protein-α. This phase I, open-label, multicenter, dose-escalation and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of FAP-IL2v in patients with advanced/metastatic solid tumors. METHODS: Participants received FAP-IL2v intravenously once weekly...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38630750/pharmacokinetic-profile-of-oral-and-subcutaneous-administration-of-paracetamol-in-the-koala-phascolarctos-cinereus-and-prediction-of-its-analgesic-efficacy
#34
JOURNAL ARTICLE
Merran Govendir, Larry Vogelnest, Amanda J Shapiro, Caroline Marschner, Benjamin Kimble
The pharmacokinetic profile of paracetamol in koalas is described when administered orally at 15 mg/kg; followed by the same dose, administered every 12 hours (hrs), repeated five times. After the initial oral administration, the median (range) maximal plasma concentration (Cmax), the time Cmax was reached (Tmax) and elimination half-life (t1/2) were 16.93 μg/mL (13.66 to 20.25 μg/mL); 4 hrs (4 to 8 hrs) and 5.54 hrs (4.66 to 7.67 hrs), respectively. When paracetamol was administered orally at 15 mg/mL every 12 hrs, the trough total plasma concentration range remained comparable to the therapeutic range in humans i...
2024: PloS One
https://read.qxmd.com/read/38630694/reducing-target-binding-affinity-improves-the-therapeutic-index-of-anti-met-antibody-drug-conjugate-in-tumor-bearing-animals
#35
JOURNAL ARTICLE
Amita Datta-Mannan, Hiuwan Choi, Zhaoyan Jin, Ling Liu, Jirong Lu, David J Stokell, Anthony T Murphy, Kenneth W Dunn, Michelle M Martinez, Yiqing Feng
Many oncology antibody-drug conjugates (ADCs) have failed to demonstrate efficacy in clinic because of dose-limiting toxicity caused by uptake into healthy tissues. We developed an approach that harnesses ADC affinity to broaden the therapeutic index (TI) using two anti-mesenchymal-epithelial transition factor (MET) monoclonal antibodies (mAbs) with high affinity (HAV) or low affinity (LAV) conjugated to monomethyl auristatin E (MMAE). The estimated TI for LAV-ADC was at least 3 times greater than the HAV-ADC...
2024: PloS One
https://read.qxmd.com/read/38630337/neuroprotective-effect-of-sterculia-setigera-leaves-hydroethanolic-extract
#36
JOURNAL ARTICLE
Yendubé T Kantati, Magloire K Kodjo, Benjamin Lefranc, Magali Basille-Dugay, Sébastien Hupin, Isabelle Schmitz, Jérôme Leprince, Messanvi Gbeassor, David Vaudry
Plants are a valuable source of information for pharmacological research and new drug discovery. The present study aimed to evaluate the neuroprotective potential of the leaves of the medicinal plant Sterculia setigera. In vitro, the effect of Sterculia setigera leaves dry hydroethanolic extract (SSE) was tested on cultured cerebellar granule neurons (CGN) survival when exposed to hydrogen peroxide (H2 O2 ) or 6-hydroxydopamine (6-OHDA), using the viability probe fluorescein diacetate (FDA), a lactate dehydrogenase (LDH) activity assay, an immunocytochemical staining against Gap 43, and the quantification of the expression of genes involved in apoptosis, necrosis, or oxidative stress...
April 17, 2024: Journal of Molecular Neuroscience: MN
https://read.qxmd.com/read/38630199/population-pharmacokinetics-of-adalimumab-in-juvenile-idiopathic-arthritis-patients-a-retrospective-cohort-study-using-clinical-care-data
#37
JOURNAL ARTICLE
Amara Nassar-Sheikh Rashid, Femke Hooijberg, Sandy C Bergkamp, Mariken P Gruppen, Taco W Kuijpers, Mike Nurmohamed, Theo Rispens, Gertjan Wolbink, J Merlijn van den Berg, Dieneke Schonenberg-Meinema, Ron A A Mathôt
BACKGROUND AND OBJECTIVE: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disorder that primarily affects the joints in children. Notably, it is known to co-occur with uveitis. Adalimumab, a monoclonal anti-TNF antibody, is effective in treating both conditions. A deeper understanding of the pharmacokinetics (PK) of adalimumab in JIA is crucial to advance in more personalized treatment approaches. The objective of this study is to evaluate the population PK profile of adalimumab in JIA and to explain causes for its variability...
April 17, 2024: Paediatric Drugs
https://read.qxmd.com/read/38630197/the-emerging-emetogenicity-of-trifluridine-tipiracil-tas%C3%A2-102-from-patient-self-reporting-a-multicenter-prospective-observational-study
#38
MULTICENTER STUDY
Hironori Fujii, Masami Tsuchiya, Daichi Watanabe, Ryo Otsuka, Daisuke Hirate, Katsuyuki Takahashi, Makiko Go, Toshihiro Kudo, Kazuhiro Shimomura, Yosuke Ando, Shinya Tani, Takao Takahashi, Katsuhisa Hayashi, Miki Chin, Naomi Matsunami, Masaya Takahashi, Akiko Hasegawa, Takashi Uchida, Hironobu Hashimoto, Akiko Kubo, Nobuhisa Matsuhashi, Akio Suzuki, Junichi Nishimura, Naoki Inui, Hirotoshi Iihara
BACKGROUND: Trifluridine/tipiracil (TAS-102) is an oral anticancer drug with adequate efficacy in unresectable colorectal cancer, but frequently also induces chemotherapy-induced nausea and vomiting (CINV). To investigate the occurrence of CINV and antiemetic therapy in patients with colorectal cancer treated with TAS-102 (JASCC-CINV 2001). METHODS: We conducted a multicenter, prospective, observational study in patients with colorectal cancer who received TAS-102 without dose reduction for the first time...
April 17, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38629757/a-prospective-cohort-study-exploring-the-effect-of-lenvatinib-planned-drug-holidays-in-treatment-of-differentiated-thyroid-cancer
#39
JOURNAL ARTICLE
Makoto Tahara, Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tsutsui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Tsuneo Imai
Background: Although lenvatinib is the preferred treatment for unresectable radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), this agent exerts considerable toxicities, which can lead to frequent dose interruptions and modifications. The adoption of planned drug holidays has been recently suggested as one means of minimizing or avoiding these severe adverse events. Our retrospective study demonstrated that planned drug holidays appear to be a promising strategy for continuing of lenvatinib...
April 17, 2024: Thyroid: Official Journal of the American Thyroid Association
https://read.qxmd.com/read/38629592/efficacy-safety-and-pharmacokinetics-of-isoniazid-affected-by-nat2-polymorphisms-in-patients-with-tuberculosis-a-systematic-review
#40
REVIEW
Thanakorn Surarak, Supatat Chumnumwat, Wichit Nosoongnoen, Pramote Tragulpiankit
N-acetyltransferase 2 (NAT2) genetic polymorphisms might alter isoniazid metabolism leading to toxicity. We reviewed the impact of NAT2 genotype status on the pharmacokinetics, efficacy, and safety of isoniazid, a treatment for tuberculosis (TB). A systematic search for research articles published in Scopus, PubMed, and Embase until August 31, 2023, was conducted without filters or limits on the following search terms and Boolean operators: "isoniazid" AND "NAT2." Studies were selected if NAT2 phenotypes with pharmacokinetics or efficacy or safety of isoniazid in patients with TB were reported...
April 2024: Clinical and Translational Science
keyword
keyword
73722
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.